about
A candidate gene approach identifies an IL33 genetic variant as a novel genetic risk factor for GCASports-related muscle injuries of the lower extremity: MR imaging appearances.Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis.Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysisThe value of repeat biopsy in lupus nephritis flares.Influence of the IL6 gene in susceptibility to systemic sclerosis.Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study.Genetic variation in the nuclear factor kappaB pathway in relation to susceptibility to rheumatoid arthritis.Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only studyGroup B streptococcal spondylodiscitis in adults: 2 case reports.Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differencesCardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review.A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosisCharacterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER).Pyogenic arthritis of native joints due to Bacteroides fragilis: Case report and review of the literatureAnalysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility.Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature.Adult-onset Still's disease with atypical cutaneous manifestations.Shrinking lung syndrome in systemic lupus erythematosus: A case series and review of the literature.Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis.Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology.Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study.Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: time for a new approach?Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature.Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus.Sjögren's syndrome-associated interstitial lung disease: A multicenter study.Diagnostic and therapeutic delay of rheumatoid arthritis and its relationship with health care devices in Catalonia. The AUDIT study.Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study.Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry.FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.Pyogenic arthritis of native joints in non-intravenous drug users: A detailed analysis of 268 cases attended in a tertiary hospital over a 22-year period.Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica.Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus.Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors.[Autoimmune cholangitis with good response to corticoids]Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital.
P50
Q28545058-A9492A28-BCCB-4D94-9EFC-0EB9CCF7AB46Q33692088-EFB0736B-EBD4-497B-BA2A-A3BFF5170E9BQ33741232-9106B3F5-5DAF-4B08-B7A2-D3EC167D18A0Q33766353-9BF75B1D-6263-4421-830D-AF41DA3C5977Q33818039-64E4EDB6-3F32-4011-94C4-F1E9BA6ADE02Q34303165-8F1FAC57-240D-499F-83A4-01C8C50134A9Q34393009-8DE9B222-4323-407E-BA98-D684D753F8D9Q34773968-D40D3357-55EE-4327-9C62-8996DF0C63E6Q35242819-CC8F733B-569D-42E9-B0BB-9D689B45E7ACQ35544546-B35A14D9-6B3F-4D09-9128-BBEF9D356B0BQ35853454-2A0D4CE2-D440-4251-8F9A-FE44AA63D3B4Q36152835-D09EF415-9C3D-4CD9-8C00-5C942126FE4DQ36153524-67EC9097-0550-4650-89BD-13CB278E4A3FQ36195807-87B59452-48D9-484A-8EB4-451B370B464DQ36245847-5005FD4F-36BD-4A05-9766-D24FAB28B4A9Q36663933-87B59AEB-CE81-4E78-90BF-63A4E8D9706AQ37205194-7AE5C18D-E65C-4D0C-921F-A42C77F23BF0Q37206928-33B316A5-001E-429F-9744-11978BD9AFABQ37467859-D6AF8CB8-F59D-4418-8224-DC2E5C3085BBQ37725331-4ABAA16D-5111-404B-B2E8-3ED55CACA0C9Q37726793-6D4BC343-80AC-4D2C-A757-D0AF0699F58AQ38199269-D17BDDE3-9C7C-42A4-A53F-A6B886FB847FQ38642663-634B395C-35B0-4695-BB70-63C75D18DF15Q38677513-01E3D712-0634-4DAC-AF54-5C1C2615414BQ38779019-ECA9B977-9FE9-4345-873D-2F7B9A960B15Q39320712-6CE48A25-8DE4-4105-95CA-3D6C337AD6A3Q40218234-962E6631-2B08-422A-91BB-36AB86F38939Q40308633-05F7FB56-D12D-4E32-A8C4-3D3BE77B8A8EQ40316161-DFD55BE7-AB73-4596-BB54-D6F35B3FB9EAQ40547141-245B0FA0-9083-4329-8E2D-2A33A34588B2Q40562190-E887366D-DE07-40B0-8AB4-9395E4237B82Q40831626-DC3C80EA-0B51-4327-8394-4562F5BE9F4FQ41139422-184424DB-E38D-49FF-8322-6FAC7D104E6EQ41433706-324361B0-546A-48BD-8D47-50599611BAA6Q41474733-7F555DEC-B1DA-42A9-B445-78D60B214F28Q41575283-ACB9DD68-7A7F-4D30-A023-F315EE5AD58EQ41680597-71E48058-0934-4C92-B1A7-F5A585AEBA34Q42632049-7E74FB83-5C58-4AD4-9038-96498257B63EQ43808849-A2CDA82A-B010-4175-B388-E64940DDC756Q43954552-155D88C5-7D91-46D1-93CC-967BAC70A243
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francisco Javier Narváez Garcia
@ast
Francisco Javier Narváez Garcia
@en
Francisco Javier Narváez Garcia
@es
Francisco Javier Narváez Garcia
@nl
type
label
Francisco Javier Narváez Garcia
@ast
Francisco Javier Narváez Garcia
@en
Francisco Javier Narváez Garcia
@es
Francisco Javier Narváez Garcia
@nl
prefLabel
Francisco Javier Narváez Garcia
@ast
Francisco Javier Narváez Garcia
@en
Francisco Javier Narváez Garcia
@es
Francisco Javier Narváez Garcia
@nl
P106
P1153
16181210000
P21
P31
P496
0000-0002-1614-8064